Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC.

Trial Profile

Phase II Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Jun 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 30 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top